Bringing tau into the limelight

Marwan Sabbagh, MD, from Barrow Neurological Institute, Phoenix, AZ gives us an overview of his talk at the Alzheimer’s Association International Conference (AAIC) 2017, London, UK. The aim of his talk was to highlight how tau, an intracellular protein should be viewed as a therapeutic target. He introduces the idea of monoclonal antibody therapy to target extracellular tau. He is hoping he can change the mindset of researchers to move away from solely focusing on amyloid, and look at how to make tau an attractive drug target. Furthermore, he explains how both proteins are equally important drug targets as Alzheimer’s disease is a biphasic disease with an amyloid driven asymptomatic phase followed by a tau driven symptomatic phase.

Share this video